Protagenic Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.

Top 15 shareholders own 30.3% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.5%	Garo Armen	738,489	US$443.1k	0.57%	no data
5.37%	Armistice Capital LLC	240,000	US$144.0k	0%	no data
3.38%	Khalil Barrage	150,880	US$90.5k	47.2%	no data
1.03%	Alexander Arrow	45,815	US$27.5k	21.2%	no data
0.83%	David Lovejoy	37,200	US$22.3k	0%	no data
0.74%	The Vanguard Group, Inc.	33,166	US$19.9k	0%	no data
0.65%	Geode Capital Management, LLC	29,130	US$17.5k	15.7%	no data
0.6%	Susquehanna International Group, LLP, Asset Management Arm	26,598	US$16.0k	0%	no data
0.48%	Osaic Wealth, Inc. , Asset Management Arm	21,414	US$12.8k	0%	no data
0.31%	State Street Global Advisors, Inc.	13,812	US$8.3k	0%	no data
0.23%	UBS Asset Management AG	10,078	US$6.0k	0%	no data
0.15%	Tower Research Capital Europe Limited	6,806	US$4.1k	17.1%	no data
0.00065%	Bank of America Corporation, Asset Management Arm	29	US$17.4	2,800%	no data
0.00002%	Carson Wealth Management Group	1	US$0.5	0%	no data
0.00002%	Morgan Stanley, Investment Banking and Brokerage Investments	1	US$0.5	0%	no data